WO2020201833A8 - Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires - Google Patents

Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires Download PDF

Info

Publication number
WO2020201833A8
WO2020201833A8 PCT/IB2020/000261 IB2020000261W WO2020201833A8 WO 2020201833 A8 WO2020201833 A8 WO 2020201833A8 IB 2020000261 W IB2020000261 W IB 2020000261W WO 2020201833 A8 WO2020201833 A8 WO 2020201833A8
Authority
WO
WIPO (PCT)
Prior art keywords
urinary tract
gepotidacin
treatment
tract infections
bacterial urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/000261
Other languages
English (en)
Other versions
WO2020201833A1 (fr
Inventor
David John Payne
Stephen Rittenhouse
Nicole SCANGARELLA-OMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/600,660 priority Critical patent/US20220184071A1/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to EP20728815.0A priority patent/EP3946342A1/fr
Priority to CN202080027022.0A priority patent/CN114828854A/zh
Priority to CA3134801A priority patent/CA3134801A1/fr
Priority to BR112021018815A priority patent/BR112021018815A2/pt
Priority to JP2021558962A priority patent/JP2022528890A/ja
Publication of WO2020201833A1 publication Critical patent/WO2020201833A1/fr
Anticipated expiration legal-status Critical
Publication of WO2020201833A8 publication Critical patent/WO2020201833A8/fr
Priority to JP2025018100A priority patent/JP2025084772A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des composés destinés à être utilisés pour traiter une infection des voies urinaires, comprenant l'administration de gépotidacine ou d'un sel pharmaceutiquement acceptable de celui-ci, dans une quantité thérapeutiquement efficace chez un être humain en ayant besoin, l'infection des voies urinaires étant provoquée par une ou plusieurs bactéries telles que définies dans la description.
PCT/IB2020/000261 2019-04-03 2020-04-03 Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires Ceased WO2020201833A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US17/600,660 US20220184071A1 (en) 2019-04-03 2019-04-03 Gepotidacin for use in the treatment of bacterial urinary tract infections
EP20728815.0A EP3946342A1 (fr) 2019-04-03 2020-04-03 Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires
CN202080027022.0A CN114828854A (zh) 2019-04-03 2020-04-03 用于治疗细菌性尿路感染的吉泊达星
CA3134801A CA3134801A1 (fr) 2019-04-03 2020-04-03 Gepotidacine destine a etre utilise dans le traitement d'infections bacteriennes des voies urinaires
BR112021018815A BR112021018815A2 (pt) 2019-04-03 2020-04-03 Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
JP2021558962A JP2022528890A (ja) 2019-04-03 2020-04-03 細菌性尿路感染症の治療に使用するためのゲポチダシン
JP2025018100A JP2025084772A (ja) 2019-04-03 2025-02-06 細菌性尿路感染症の治療に使用するためのゲポチダシン

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201962828801P 2019-04-03 2019-04-03
US62/828,801 2019-04-03
US201962834112P 2019-04-15 2019-04-15
US62/834,112 2019-04-15
US201962841384P 2019-05-01 2019-05-01
US201962841375P 2019-05-01 2019-05-01
US201962841363P 2019-05-01 2019-05-01
US62/841,384 2019-05-01
US62/841,375 2019-05-01
US62/841,363 2019-05-01
US201962895590P 2019-09-04 2019-09-04
US201962895594P 2019-09-04 2019-09-04
US201962895601P 2019-09-04 2019-09-04
US62/895,601 2019-09-04
US62/895,594 2019-09-04
US62/895,590 2019-09-04

Publications (2)

Publication Number Publication Date
WO2020201833A1 WO2020201833A1 (fr) 2020-10-08
WO2020201833A8 true WO2020201833A8 (fr) 2022-08-04

Family

ID=70861514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/000261 Ceased WO2020201833A1 (fr) 2019-04-03 2020-04-03 Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires

Country Status (6)

Country Link
EP (1) EP3946342A1 (fr)
JP (2) JP2022528890A (fr)
CN (1) CN114828854A (fr)
BR (1) BR112021018815A2 (fr)
CA (1) CA3134801A1 (fr)
WO (1) WO2020201833A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4288035A1 (fr) 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Formulations en doses solides administrées par voie orale
JP2025502442A (ja) * 2022-01-21 2025-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｓａｐｒｏｐｈｙｔｉｃｕｓによって引き起こされる感染症の処置における使用のためのゲポチダシンおよびバンコマイシン
EP4316463A1 (fr) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Nouvelle formule
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001097863A (ja) * 1999-09-24 2001-04-10 Smithkline Beecham Corp 嫌気性病原菌に対するフルオロキノロン化合物の使用法
AU2008240764C1 (en) 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
US10702521B2 (en) * 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

Also Published As

Publication number Publication date
JP2022528890A (ja) 2022-06-16
JP2025084772A (ja) 2025-06-03
BR112021018815A2 (pt) 2022-03-03
CA3134801A1 (fr) 2020-10-08
EP3946342A1 (fr) 2022-02-09
WO2020201833A1 (fr) 2020-10-08
CN114828854A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
WO2020201833A8 (fr) Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
PH12020551905A1 (en) C-mannoside compounds useful for the treatment of urinary tract infections
MX2009009918A (es) Medicamentos combinados para el tratamiento de infecciones bacterianas.
WO2009088549A3 (fr) Procédés d'inhibition de la virulence bactérienne et composés s'y rapportant
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
PH12019501245A1 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
WO2023081830A3 (fr) Compositions et traitements à base de nirogacestat
CR20230510A (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
IL296890A (en) Caspase inhibitors to enhance injury repair and to treat bacterial and viral infections
EA202092579A1 (ru) Оксозамещенное соединение
WO2021231931A8 (fr) Procédés de traitement d'infections par le sras-cov-2
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
EA202193211A1 (ru) Лечение синуклеопатий
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
WO2007023072A3 (fr) Utilisation d'ambroxol pour traiter les infections a rhinovirus
ATE495186T1 (de) Antibakterielle amid-makrozyklen iv
WO2022048618A8 (fr) Méthodes de traitement des maladies inflammatoires de l'intestin
WO2023183820A3 (fr) Agents thérapeutiques pour traiter une infection des voies respiratoires dirigés contre la covid-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20728815

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3134801

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021558962

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020728815

Country of ref document: EP

Effective date: 20211103

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021018815

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112021018815

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210921